Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers
Study Details
Study Description
Brief Summary
Rationale: Early in the covid-19 pandemic, it was unclear whether and how individuals and populations would develop protective and enduring immunity against SARS-CoV-2, either after infection or vaccination. It is still not clear what role might immune cellular responses play in the development of immunity to SARS-CoV-2 infection and what are the implications for vaccines? As T cells recognise and respond to viral antigens they produce many protective reactions and effector molecules. One such molecule is the cytokine interferon γ, secreted by CD4+ and CD8+ T cells and their memory cells. This can be measured means of documenting specific T cell responses to viral antigens. Published studies offered a strong evidence that T cell immune responses are sustained, even in the face of declining or undetectable antibodies, implying that some immunity persists. The evidence from new studies, interim results from phase III vaccine trials, and previous data from phase I and phase II trials support the notion that memory T cell responses to the vaccines, along with B cell antibody responses, should provide good and possibly enduring immunity to SARS-Cov-2. We propose to describe and characterize the humoral, innate and long-term adaptive immune responses and the neutralization potential generated by COVID-19 vaccination (Covaxin, Covishield) among healthcare and frontline workers.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Study objectives i. To estimate the neutralizing antibodies titre against SARS CoV-2 by vaccine type.
-
To estimate the proportion of vaccine recipients developing effective antibody response for SARS-CoV-2 specific IgG, IgM, and total IgE and IgA antibodies pre- and post-COVID-19 vaccination on day zero, day 28, month 2, 3, 6, 12, 18 and 24 by vaccine type.
-
To identify and characterize the immune biomarkers for long term innate and adaptive immune response by vaccine type.
-
To estimate the ratio of immune biomarker levels between pre- and post- COVID-19 vaccination at days 28, month 2, 3, 6, 12, 18 and 24 by vaccine type
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Group 1 COVISHIELD Participants will receive one dose of COVID-19 vaccine (Covishield) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly. |
|
| Group 2 COVAXIN Participants will receive one dose of COVID-19 vaccine (Covaxin) at baseline and one second dose after 28 days (Window period of +3 days) intra muscularly. |
Outcome Measures
Primary Outcome Measures
- Antibody titers [2 years]
IgM and IgG SARS-Cov2 specific antibody titres and IgA and IgE (total)
- Ratio of immune biomarker production [2 years]
The ratio of immune biomarkers production between pre and post COVID-19 vaccination
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adults aged 18-60 years
-
Should have been vaccinated with either Covaxin or Covishield
-
Willing to provide written informed consent
Exclusion Criteria:
-
Participants will be ineligible if they are not vaccinated for either Covaxin or Covishield vaccine
-
Not willing to provide written informed consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Institute for Research in Tuberculosis | Chennai | Tamilnadu | India | 600031 |
Sponsors and Collaborators
- Tuberculosis Research Centre, India
- National Institute of Epidemiology
Investigators
- Principal Investigator: PAVAN Kumar, PhD, National Institute for Research in Tuberculosis
- Principal Investigator: BANUREKHA V V, MBBS, MPH, National Institute for Research in Tuberculosis
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021 007